-
Part 2 | Session 7 Plenary session 10 – Management of diabetes with kidney disease
-
Part 2 | Session 8 Plenary session 11 – Managing frail and elderly patients
-
Part 2 | Session 9 Plenary session 12 – Managing end-stage disease: focus on QoL
-
Part 1 | Session 1 Plenary session 1 – HFpEF
-
Part 1 | Session 3 Plenary session 2 – SGLT2 updates
-
Part 1 | Session 5 Plenary session 3 – Weight management in CRM disease
-
Part 1 | Session 7 Plenary session 4 – Guidelines implementation for acutely ill patients
-
Part 1 | Session 8 Plenary session 5 – Mineralocorticoids antagonists in CRM disease
-
Part 1 | Session 10 Plenary session 6 – Diuretics: old drugs, new data, new approaches
-
Part 2 | Session 5 Plenary session 9 – Managing “metals”
e-SPACE Cardio-Renal-Metabolic 2023 was the third edition of the annual global online conference that explores how leading experts, in cardiology, nephrology, and diabetology, are treating the interrelated diseases.
Course leadership Prof Stefan Anker (Berlin, DE), Dr Javed Butler (Texas, US), Prof Antonio Ceriello (Milan, IT), Prof Tara I Chang (California, US), Prof Ian de Boer (Washington, US), Prof Peter Rossing (Copenhagen, DK) and Prof Shelley Zieroth (Winnipeg, CA) lead an interactive programme of plenary sessions, meet the expert, case discussions and satellite symposium sessions focusing on the patient journey.
For the first time, e-SPACE Cardio-Renal-Metabolic 2023 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, alongside KDIGO's mission to improve the care and outcomes of patients with kidney disease worldwide through the development and implementation of global clinical practice guidelines, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
Learning Objectives
- Review the burden of diabetes, kidney disease and heart failure including morbidity, excess mortality, and reduced quality of life affecting individuals around the world
- Describe the complexity and interlink between the three conditions
- Discuss existing guidelines and best approaches for screening patients
- Review evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity including SLGT2i, GLP-1RA, new non-steroidal mineralocorticoid receptor antagonists and other emerging therapies
- Foster cross-collaboration between other cardiorenal / metabolic specialists and primary care physicians and allied health care professionals in order to improve patients outcomes
Target Audience
- Cardiologists
- Nephrologists
- Diabetologists
- General Practitioners (GPs)
- HF Specialists
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Part 1
Day One
Part 2
Day Two
Faculty Biographies
Matthew R Weir
Director of the Division of Nephrology
Dr Matthew R Weir is Director of the Division of Nephrology and attending physician at University of Maryland, Maryland, US.
He received his medical degree from the University of Virginia, Charlottesville and has written more than 600 manuscripts and book chapters.
Dr Weir is on the editorial board of 22 journals and is Section Editor of Current Hypertension Reports and Current Opinion in Hypertension and Nephrology, and Associate Editor of Clinical Nephrology and the American Journal of Nephrology.
Andrew JS Coats
Professor of Cardiology and Scientific Director
Professor Andrew Coats was born in Melbourne, Australia. He studied at St Catherine’s College, Oxford, where he earned a B.A. in Physiological Sciences with First-Class Honours, and then completed his medical degree (M.B. B.Chir.) at Clare College, Cambridge. He later obtained higher doctorates (D.M. and D.Sc.) in recognition of his substantial contributions to cardiovascular medicine, and he also completed an MBA at the London Business School. Professor Coats serves as Editor-in-Chief of the Cardiac Failure Review journal.
Career Overview
Andrew Coats is an internationally renowned academic cardiologist, inventor, and university leader with a career spanning more than three decades. He is currently the Scientific Director and CEO of the Heart Research Institute in Sydney, Australia. He also serves as Dean of the Royal Australasian College of Physicians, Affiliate Professor at Deakin University, and Emeritus Professor of Medicine at Monash University.
…
Shelley Zieroth
Director, Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.
Kieran McCafferty
Consultant Nephrologist
Dr Kieran McCafferty is a Consultant Nephrologist at Barts Health NHS Trust and a Senior Lecturer at Queen Mary University of London. His clinical work is focused on the care of patients with complex kidney disease, with particular expertise in diabetic kidney disease and haemodialysis. Alongside his clinical responsibilities, Dr McCafferty has developed a strong academic and leadership profile within nephrology and clinical research, with a clear emphasis on improving patient-centred outcomes through high-quality clinical trials.
Academic History
Dr McCafferty holds an academic appointment as Senior Lecturer at Queen Mary University of London, reflecting his combined clinical and research roles. His academic interests bridge basic science and clinical medicine, with a particular focus on uraemic cardiovascular disease and mechanisms of cardiovascular protection in patients with chronic kidney disease.
While his foundational research interests lie…
Comments